A Phase 4 interventional study of Placebo and Exenatide in Diabetes Mellitus, Type 2, sponsored by The University of Texas Health Science Center at San Antonio. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-24.
Sponsored by The University of Texas Health Science Center at San Antonio · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies testing exenatide in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Exenatide · Diabetes Mellitus, Type 2.
Among the 127 studies testing exenatide in Diabetes Mellitus, Type 2, this one is the 57th largest by enrollment, is the only one that started in 2018, is one of 46 in phase 4, and was the 124th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 127 studies testing exenatide in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Exenatide: first FDA approval 2005 (BYETTA), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 13 · Phase 3 51 · Phase 4 46
First in 2002; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 90 across the 127 interventional studies. Of the 112 that completed or were terminated, 61 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 127 have an industry lead sponsor. The 10 most frequent:
The University of Texas Health Science Center at San Antonio is the lead sponsor of 445 studies on the registry; 89 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 35 (54%) have results posted.
42 studies in Diabetes Mellitus, Type 2 by The University of Texas Health Science Center at San Antonio: 10 open now, 10 under way, 1 of them phase 3. Of 31 finished, 19 (61%) have results posted.
Among the 42 studies in Diabetes Mellitus, Type 2 by The University of Texas Health Science Center at San Antonio, this one is the 8th largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2018, is one of 14 in phase 4, and was the 24th registered.
The University of Texas Health Science Center at San Antonio’s Diabetes Mellitus, Type 2 studies by the year they started, since 1979.
None of the studies under way reaches primary completion within a year.
Among the 127 studies testing exenatide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among The University of Texas Health Science Center at San Antonio’s 42 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
Research Design/Plan: After screening, each subject will receive 1 measurements of Endogenous Glucose Production [EGP] with prime-continuous Infusion of 3-3H-glucose. After completing the EGP measurement each subject will receive a Double Tracer Oral Glucose Tolerance Test [OGTT].
Methods: Visit 1: Screening. Medical history will be obtained, physical exam performed, and pregnancy test performed.
Visit 2: Endogenous Glucose Production Measurement: The rate of EGP will be measured with 3-3H-glucose.
Visit 3: Double Tracer OGTT
Eligible subjects will receive a measurement of endogenous glucose production (EGP) with a prime-continuous infusion of 3-3H-glucose. The EGP measurement will be performed in the morning after a 10-12 hour overnight fast and will last 8 hours (from 6 AM to 2 PM). After a 3-hour tracer equilibration period, subjects (20 per group) will receive one of the following medications: (i) placebo; (ii) exenatide 5 ug subcutaneously; (iii) dapagliflozin (10 mg); and (iv) dapagliflozin 10 mg plus exenatide 5 ug. Following the test medication at 9 AM, blood samples will be drawn every 15 minutes for an additional 5 hours and plasma glucose, insulin, C-peptide, glucagon, cortisol, growth hormone, and catecholamine concentrations and glucose specific activity will be measured.
Visit 1: Screening. Medical history \& physical exam will be performed. Blood will be drawn for fasting plasma glucose [FPG], routine blood chemistries, complete blood count [CBC], lipid profile, HbA1c, and thyroid function [TSH], Urinalysis, electrocardiogram [EKG], albumin/creatinine ratio and pregnancy test will be performed.
Visit 2: EGP Measurement: The rate of endogenous glucose production will be measured with 3-3H-glucose infusion. [3-3H]-glucose infusion will be started at 6 in the morning [AM] and continued until 2:30 afternoon [PM](5 hours after drug administration). At 6 AM a catheter will be placed into an anticubital vein and a prime (40 uCi x FPG/100)- continuous (0.4 uCi) infusion of [3-3H]- glucose will be started and continued until 2:30 PM. (5 hours after drug administration). Participant's hand will be placed in a box heated to 50-60°C (122-140°F). Baseline blood samples will be obtained at-210, -60, -50, -45, -40, -35, -30, -20, -10, and 0 . After 3.5 hours of tracer equilibration blood samples will be obtained every 10-20 minutes from 9 AM to 2 PM. Plasma glucose, insulin, C-peptide, glucagon, cortisol, growth hormone, and catecholamine concentrations, and [3-3H]-glucose specific activity will be measured. Urine will be collected from 6 to 9 AM and from 9 AM to 2 PM. Urinary volume and glucose concentration will be measured and urinary glucose excretion rate calculated. The study will end at 2:30 PM.
Visit 3: Double Tracer Oral Glucose Tolerance Test [OGTT]: Within the week after the measurement of EGP, all subjects will have a 5-hour OGTT with measurement of plasma glucose, insulin (I), C-peptide (CP), and glucagon concentrations at -180, -6-, -5-, -45, -40, -35, -30, -20, -10, 0 and every 15-30 minutes thereafter to obtain a measure of overall glucose tolerance, insulin secretion (CP0-120/G0-120), insulin sensitivity ([Matsuda Index=MI]), beta cell function, (CP0-120/G0-120 x MI), and suppression of plasma glucagon concentration (64). At 7 AM a catheter will be placed into an antecubital vein and a prime (25 uCi x FPG/100)- continuous (0.25 uCi) infusion of [3-3H]- glucose will be started and continued until 3 PM. Urinary volume and glucose concentration will be measured and urinary glucose excretion rate calculated.
HbA1c will be measured 2x, 1 on the day of the OGTT \& 1 on the day of the EGP measurement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
Drug: Placebo
we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
Drug: Exenatide
we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
Drug: Dapagliflozin
we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
Drug: Exenatide and Dapagliflozin
Placebo will be administered to 20 subjects after a 3 hour tracer equilibration period
Also known as: Placebo drug
Exenatide will be administered to 20 subjects after a 3 hour tracer equilibration period
Also known as: Byetta, Bydureon
Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
Also known as: Farxiga
Drug pages: ExenatideStudies of ExenatideExenatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DapagliflozinStudies of DapagliflozinDapagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Exenatide and Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
Also known as: Byetta plus Dapagliflozin
Change in EGP From Baseline to Post-oral Glucose Load.
The difference in rate of EGP during the last hour of the study (from 240-300 minutes) between drug-treatment and placebo treatment studies represents the effect of drug treatment on EGP, which will be compared among the 3 acute drug treatments (exenatide; dapagliflozin; exenatide plus dapagliflozin this data includes change in EGP above baseline following dapagliflozin alone vs dapagliflozin/exenatide) with ANOVA.
Time frame: From baseline [-35 to 0min] to the last hour post-glucose load [240-300 minutes]
| Milestone | Type 2 Diabetes on Dapagliflozin | Type 2 Diabetes on Oral Placebo | Type 2 Diabetes on Exenatide | Type 2 Diabetes on Exenatide Plus Dapagliflozin |
|---|---|---|---|---|
| Started | 30 | 23 | 28 | 26 |
| Completed | 25 | 15 | 25 | 25 |
| Not completed | 5 | 8 | 3 | 1 |
The difference in rate of EGP during the last hour of the study (from 240-300 minutes) between drug-treatment and placebo treatment studies represents the effect of drug treatment on EGP, which will be compared among the 3 acute drug treatments (exenatide; dapagliflozin; exenatide plus dapagliflozin this data includes change in EGP above baseline following dapagliflozin alone vs dapagliflozin/exenatide) with ANOVA.
| mg/kg.min | Placebo | Exenatide | Dapagliflozin | Exenatide and Dapagliflozin |
|---|---|---|---|---|
| Change in EGP From Baseline to Post-oral Glucose Load. | -0.03 ± 0.02 | -0.18 ± 0.02 | 0.14 ± 0.03 | -0.08 ± 0.03 |
Collected over 4 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Exenatide | 0/25 (0%) | 0/25 (0%) | 4/25 (16%) |
| Dapagliflozin | 0/25 (0%) | 0/25 (0%) | 7/25 (28%) |
| Exenatide and Dapagliflozin | 0/25 (0%) | 0/25 (0%) | 6/25 (24%) |
| Event | Placebo | Exenatide | Dapagliflozin | Exenatide and Dapagliflozin |
|---|---|---|---|---|
| Genital MycosisInfections and infestations | 0/15 | 0/25 | 7/25 | 4/25 |
| Nausea and VomitingGastrointestinal disorders | 0/15 | 4/25 | 0/25 | 2/25 |
| Age, Continuous(years) | Placebo | Exenatide | Dapagliflozin | Exenatide and Dapagliflozin | Total |
|---|---|---|---|---|---|
| Mean | 54 ± 3 | 52 ± 3 | 51 ± 2 | 49 ± 2 | 51 ± 3 |
| Sex: Female, Male(Participants) | Placebo | Exenatide | Dapagliflozin | Exenatide and Dapagliflozin | Total |
|---|---|---|---|---|---|
| Female | 10 | 17 | 15 | 16 | 58 |
| Male | 5 | 8 | 10 | 9 | 32 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Exenatide | Dapagliflozin | Exenatide and Dapagliflozin | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 15 | 14 | 16 | 56 |
| Not Hispanic or Latino | 2 | 10 | 11 | 9 | 32 |
| Unknown or Not Reported | 2 | 0 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Placebo | Exenatide | Dapagliflozin | Exenatide and Dapagliflozin | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 0 | 0 | 2 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 7 | 9 | 8 | 28 |
| White | 9 | 18 | 16 | 17 | 60 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| ENDOGENOUS GLUCOSE PRODUCTION [EGP](mg/kg.min) | Placebo | Exenatide | Dapagliflozin | Exenatide and Dapagliflozin | Total |
|---|---|---|---|---|---|
| Mean | 2.30 ± 0.05 | 2.33 ± 0.13 | 2.27 ± 0.04 | 2.41 ± 0.10 | 2.33 ± 0.25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All collected IPD, all IPD that underlie results in a publication
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be shared once study closes to enrollment and all data are analyzed and published. Informed consent documentation will be available for sharing.....
Access criteria: Access will be available through the journal website and on request through the PI.
Ran from Feb 2018 to primary completion in Mar 2022, 49 months.
Results were first posted in Jul 2023, 1 year 3 months after primary completion.
Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's 49 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Exenatide · Dapagliflozin
The University of Texas Health Science Center at San Antonio →